Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-508
- Development stage
- Unknown
- Lead developer
- Housey Pharmaceutical Research Laboratories
- Modality
- Small Molecules
01
Overview
HP-508 is an experimental small molecule therapeutic candidate being developed by Housey Pharmaceutical Research Laboratories for the treatment of Type 1 Diabetes. Discovered using the company's proprietary cell-based assay systems, HP-508 is designed to stimulate the regeneration of pancreatic beta cells. This approach aims to restore endogenous insulin production in patients whose beta cells have been destroyed by autoimmune processes, potentially reducing or eliminating the need for exogenous insulin therapy. The candidate is currently in Phase 1 clinical development.
Beyond the preview
Go deeper on HP-508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-508.